NCT02078219 - Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia | Biotech Hunter

Enrollment

204

Participants

Timeline

Start Date

January 5, 2014

Primary Completion Date

March 13, 2015

Study Completion Date

March 13, 2015

Conditions

Gout and Hyperuricemia

Interventions

DRUG

RDEA3170

Oral Treatment

DRUG

Allopurinol

Oral Treatment

DRUG

Placebo

Oral Treatment

Trial Locations (14)

182-0006

Research Site, Chofu-shi

812-0027

Research Site, Fukuoka

819-0006

Research Site, Fukuoka

819-8551

Research Site, Fukuoka

807-0857

Research Site, Kitakyushu-shi

270-0021

Research Site, Matsudo-shi

278-8501

Research Site, Noda

144-0034

Research Site, Ōta-ku

339-8521

Research Site, Saitama-shi

980-0011

Research Site, Sendai

981-0923

Research Site, Sendai

983-0039

Research Site, Sendai

983-0835

Research Site, Sendai

141-6003

Research Site, Shinagawa-ku